Biofrontera Inc. (BFRIW)
0.07
0.01 (7.69%)
At close: Apr 14, 2025, 1:58 PM
Company Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.
It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo.
The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 92 |
| CEO | Dr. Hermann Luebbert Ph.D. |
Contact Details
Address: 120 Presidential Way Woburn, Delaware United States | |
| Website | https://www.biofrontera-us.com |
Stock Details
| Ticker Symbol | BFRIW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001858685 |
| CUSIP Number | 09077D118 |
| ISIN Number | US09077D1182 |
| Employer ID | 47-3765675 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Hermann Luebbert Ph.D. | Chief Executive Officer, President & Chairman |
| Eugene Frederick Leffler III | Chief Financial Officer |
| Daniel Hakansson J.D. | General Counsel & Head of Compliance |
| Erica F. Gates CPA, M.B.A. | Senior Director of Finance & Principal Accounting Officer |
| Jon Lyons M.B.A., Ph.D. | Vice President of Scientific & Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |
| Feb 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 29, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 17, 2025 | S-1 | Filing |
| Dec 20, 2024 | SCHEDULE 13D/A | [Amend] Filing |
| Dec 05, 2024 | D | Filing |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |